IPP Bureau
Abbott India posts Q4 FY24 PAT at Rs. 287.06 Cr
By IPP Bureau - May 10, 2024
The company has posted net profit of Rs. 1,201.22 crores for the Financial Year ended March 31, 2024
Medico Remedies posts Q4 FY24 PAT at Rs. 3.09 Cr
By IPP Bureau - May 10, 2024
The company has posted net profit of Rs.8.29 crores for the Financial Year ended March 31, 2024
Alembic Pharmaceuticals posts Q4 FY24 PAT at Rs. 178.21 Cr
By IPP Bureau - May 10, 2024
The company has posted net profit of Rs.615.82 crores for the Financial Year ended March 31, 2024
Cipla receives 1 observation from USFDA for Kurkumbh facility
By IPP Bureau - May 10, 2024
The company is committed to address this observation comprehensively within stipulated time
Vijaya Diagnostic Centre posts Q4 FY24 consolidated PAT at Rs. 33.45 Cr
By IPP Bureau - May 09, 2024
The company has posted net profit of Rs.118.82 crores for the Financial Year ended March 31, 2024
Piramal Pharma launches new campaign for 'Polycrol' with Brand Ambassador Jisshu Sengupta
By IPP Bureau - May 09, 2024
the campaign emphasizes the brand's reliability and effectiveness in providing timely relief
Gland Pharma receives approval for Edaravone Injection
By IPP Bureau - May 09, 2024
The product is used to treat amyotrophic lateral sclerosis
Ashland signs definitive agreement to sell nutraceuticals business to Turnspire Capital Partners
By IPP Bureau - May 09, 2024
Ashland's nutraceuticals business supplies a broad portfolio of active ingredients and formulation aids to nutritional product companies
Aarti Drugs posts Q4 FY24 consolidated PAT at Rs. 47.37 Cr
By IPP Bureau - May 09, 2024
The company has posted net profit of Rs.171.42 crores for the Financial Year ended March 31, 2024
WACKER expands production capacity for biopharmaceuticals in San Diego
By IPP Bureau - May 08, 2024
Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA
Sumitomo Corporation makes full-scale entry into private clinic business in fast-growing southeast Asia
By IPP Bureau - May 08, 2024
Investing in Malaysia's largest clinic operator to expand the healthcare business
AstraZeneca’s Calquence combination regimen demonstrated positive results in 1st-line mantle cell lymphoma in ECHO Phase III trial
By IPP Bureau - May 08, 2024
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
USFDA accepts Bristol Myers Squibb’s application for subcutaneous nivolumab
By IPP Bureau - May 08, 2024
Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor
AstraZeneca completes equity investment agreement with Cellectis
By IPP Bureau - May 08, 2024
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
Aptar Closures introduces new e-Commerce disc top closure for beauty, personal and home care applications
By IPP Bureau - May 08, 2024
Aptar Closures’ E-Disc Top securely protects against in-transit leakage while eliminating the need for liners and extra shipping preparation fees
